
Keywords: uPA; urokinase plasminogen activator; PAI-1; plasminogen activator inhibitor 1; ctDNA; circulating tumor DNA; CTC; circulating tumor cells; PFS; progression-free survival; pCR; pathological complete response; SNVs; single nucleotide variants; CNVs; copy n